Gnosis is proud to announce that its commitment to providing innovative solutions to global well-being and health care challenges has been rewarded at NutraIngredients Award 2016, winning in the FINISHED PRODUCT OF THE YEAR – medical food category with XaQuil™ XR from XYMOGEN, a new finished product formulated with Quatrefolic®.
At Vitafoods, NutraIngredients Awards 2016 celebrated innovation and research of the global nutritional industry, awarding companies and products that, by seizing the most recent compelling nutritional needs, really bring tangible benefits to humans well-being.
XaQuil™ XR, formulated with Quatrefolic® and developed through a fruitful partnership between XYMOGEN and Gnosis, triumphed as Finished Product of the Year in the Medical Food category.
The independent 10-person judging panel evaluated the true innovation, the validated research and the ability to recognize and fill a gap in the healthy product sector. XaQuil™ XR by XYMOGEN is an innovative medical food formulated with Quatrefolic®, and used as an adjunctive treatment for depression. XaQuil™ XR fulfills the emergent scientific demand that have compelled psychiatrists to consider augmenting traditional antidepressants with the medical food L-methylfolate.
Quatrefolic® in XaQuil™ XR is the glucosamine salt of the 5-methyltetrahydrofolate (5-MTHF), the metabolic active form of folate.
The specific & patented extended-release profile of Quatrefolic® was chosen in order to replicate what happens into the intestine to dietary folate.
Medical food industry is expanding and is driven by the rise in aging population, the shift to enteral nutrition and a demand for personalized medicine. XaQuil™ XR offers the most bioavailable form of reduced folate available in the market, Quatrefolic®, the glucosamine salt of the 5-MTHF, in an innovative, orally administered, extended-release formulation.
About XaQuil™XR
XaQuil™XR is an innovative medical food formulated with Quatrefolic® where the release of the active ingredients is tightly controlled for an optimization of the blood levels of 5-MTHF and can be used as an adjunctive treatment for depression.
XaQuil™XR may constitute an effective, safe, and well tolerated medical food strategy for patients with major depressive disorder who have a partial response or no response to SSRIs (Selective Serotonin Reuptake Inhibitors).
In XaQuil™XR Quatrefolic® provides folate in the already biologically active form of 5-methyltetrahydrofolate, without any kind of metabolization. 5-MTHF can reach the systemic circulation and cross the blood-brain barrier, and enter straight the brain cell, for direct utilization in the folate cycle.
Gnosis and Xymogen have been working together to develop an unique extended release formulation in tablets with specific release profile of the active ingredient useful to increase the folate levels. The XaQuil™XR formulation allows a time dependent release of the 5-MTHF in the gastroenteric system, followed by a time-dependent release of the active in the plasma. Extended-release of 5-MTHF may be crucial in partial response or no response subjects to SSRIs because normalizes the blood folate level and maximizes efficacy of XaQuil™XR.
XaQuil™XR. extended-release coating technology is property of Gnosis S.p.A (International Application PCT/IB2014/065852).
About Xymogen
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
